The Hindu Business Line : Ranbaxy's loss may be gain for Dr Reddy's

NEW DELHI: The delay in Ranbaxy Laboratories getting approval from the USFDA for launching generic version of GlaxoSmithKline's (GSK) migraine and headache drug Imitrex could turn out to be a gain for Hyderabad-based Dr Reddy's Laboratories, which has al ready launched the drug in the US.

According to analysts, Dr Reddy's (DRL) could end up gaining a major chunk of the estimated $80 million sales from the drug by Ranbaxy in the first year of launch in the US.

Dr Reddy's, which is the authorised generic manufacturers from GSK had already launched the drug in November last year.

“Ranbaxy was expecting a sale of up to $80 million from generic Imitrex but now DRL is the only generic manufacturer of the drug,”

Sarvajit Kaur, Analyst of Angel Broking, said, adding that the advantage is with DRL to garner a large chunk if Ranbaxy failed to launch the drug anytime soon.

Ranbaxy has not got approval from the USFDA for launching the generic copy of Imitrex after it came under the scanner of the health regulator, which last year banned 30 of its generic drugs produced at Dewas and Poanta Sahib units.

On the other hand, DRL launched the generic version of Imitrex in November last year after settling patent litigation with GSK, thus becoming the first company to launch an authorised generic version of the drug. - PTI

Prev: Rupee rises
Next: Unitech not worried about market capitalisation losses

Business Line | NUS Index |